<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481831</url>
  </required_header>
  <id_info>
    <org_study_id>zhiruo</org_study_id>
    <nct_id>NCT01481831</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting</brief_title>
  <acronym>ESPNV</acronym>
  <official_title>A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the efficacy and safety of single and repeated
      doses of palonosetron hydrochloride in preventing nausea and vomiting caused by moderate and
      highly emetogenic chemotherapy in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including
      Cisplatin≥50mg/m2, Carmustine&gt;250mg/m2, Cyclophosphamide&gt;1500mg/m2, Dacarbazine&gt;60mg/m2,
      Doxorubicin&gt;60mg/m2, Epirubicin&gt;90mg/m2, IFO≥10g/m2 or AC program.

      Group II (Moderately Emetogenic Chemotherapy): Patients that accepted chemotherapy including
      any dose of Carboplatin, Daunorubicin, Oaliplatin, Irinotecan, or Doxorubicin&lt;60mg/m2(not
      include liposomal doxorubicin), Epirubicin≤90mg/m2, Carmustine≤250mg/m2,
      Methotrexate≥250mg/m2, Cyclophosphamide≤1500mg/m2, Arabinoside&gt;200mg/m2, IFO&lt;10g/m2,
      Cisplatin≥50mg/m2.

      Total subjects: 1000, single dose of palonosetron group of 500 patients, repeated doses of
      palonosetron group of 500 patients. According to the study subjects receiving highly
      emetogenic chemotherapy or moderately emetogenic chemotherapy, subjects are stratified
      randomize.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>2-7 days</time_frame>
    <description>defined as no emetic episode and no use of rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>0-24 hours, 0-7 days</time_frame>
    <description>defined as no emetic episode and no use of rescue medication</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">599</enrollment>
  <condition>Neoplasms</condition>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>H PALO day 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H PALO day 1,3,5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M PALO day 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M PALO day 1,3,5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride</intervention_name>
    <description>0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.</description>
    <arm_group_label>H PALO day 1</arm_group_label>
    <arm_group_label>M PALO day 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride</intervention_name>
    <description>0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.</description>
    <arm_group_label>H PALO day 1,3,5</arm_group_label>
    <arm_group_label>M PALO day 1,3,5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients candidates to a chemotherapy treatment, with histologically or cytologically
             confirmed malignant disease;

          2. The concrete chemotherapy plan does not limited, group I (Highly Emetogenic
             Chemotherapy), group II (Moderately Emetogenic Chemotherapy);

          3. Male or female aged 18-75 years, ECOG≤2, estimates survival time≥3 months;

          4. WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥80×109/L, total bilirubin≤1.5×ULN(Normal value upper
             limit), AST and ALT≤2.5×ULN(With transferability liver cancer≤5×ULN), Cr and
             BUN≤1.5×ULN, electrolyte and electrocardiogram are normal, conforms to the
             chemotherapy adaptation;

          5. Patients have been apart from the previous chemotherapy to finish above 2 weeks
             (including 2 weeks);

          6. Patients that voluntarily sign the consent form.

        Exclusion Criteria:

          1. Pregnancy, or patients during breast feeding;

          2. Patients have accepted any radiotherapy during the experimental period;

          3. Gastric outlet or intestinal obstruction;

          4. Patients have serious heart diseases, liver kidney diseases, or metabolism function
             disorder;

          5. Patients have epilepsy, or have been used psychotropic drug and calm drug;

          6. Received any drugs with potential anti-emetic efficacy, or experienced any vomiting,
             nausea or retching in the 24 hours prior to chemotherapy;

          7. Patients with transferability brain tumor, have vomiting caused by skull high
             pressure, or can not speak sickness situation and adverse reactions by self;

          8. Patients have known hypersensitivity to 5-HT3 antagonists;

          9. Patients have chemotherapy contraindications;

         10. Patients are participating, or have participated in other Clinical studies of new
             drugs within 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA 301 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA 307 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Military Command</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangxi Cancer Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Command</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Wuxi</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Medical College Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital of Fourth Military Medical University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>December 28, 2012</last_update_submitted>
  <last_update_submitted_qc>December 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Zhan Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

